Trigger Finger (Adult)

1. Clinical Overview

Summary

Trigger Finger (Stenosing Tenosynovitis) is a common, mechanically-driven disorder characterized by painful catching, clicking, or locking of a digit during flexion-extension movements. The core pathology is a mismatch between the volume of the flexor tendon-sheath complex and the diameter of the first annular (A1) pulley, creating a functional stenosis. As the digit flexes, a nodule or thickened segment of tendon is pulled into the pulley; upon attempted extension, the nodule becomes temporarily entrapped, causing the characteristic "trigger" or "snap" as it passes through the constricted pulley. [1,2,3]

The condition affects approximately 2-3% of the general adult population, with a marked female predominance (6:1) and peak incidence in the 5th-6th decades of life. Prevalence increases substantially in patients with diabetes mellitus (10-20%), rheumatoid arthritis, and hypothyroidism. The ring and middle fingers are most commonly affected, followed by the thumb, index, and little fingers. [4,5]

Diagnosis is clinical, based on history of triggering and palpation of a tender nodule at the A1 pulley level (palmar metacarpal head). Management follows an evidence-based stepwise approach: activity modification and splinting for mild cases; corticosteroid injection for moderate severity (60-90% cure rate in non-diabetics); and open or percutaneous A1 pulley release for refractory cases or severe contracture. Surgical release has a near 100% success rate with low complication risk. [6,7]

Key Facts

The Mechanical Problem: Trigger finger is fundamentally a problem of pulley-tendon mismatch. Thickening of the A1 pulley (stenosis) and/or nodular enlargement of the flexor tendon creates mechanical obstruction. The flexor muscles are powerful enough to pull the nodule into the pulley during flexion, but the weaker extensor mechanism cannot easily pull it out during extension, leading to the characteristic triggering or locking phenomenon.

The Critical Site - A1 Pulley: The A1 pulley overlies the metacarpal head at the level of the distal palmar crease. It is the only pulley that can be safely divided without functional consequence. The A2 (over proximal phalanx) and A4 (over middle phalanx) pulleys are biomechanically critical and must be preserved to prevent bowstringing and loss of mechanical advantage. [8]

Diabetes Connection: Diabetes mellitus is the strongest modifiable risk factor, with 10-20% lifetime prevalence (compared to 2-3% in non-diabetics). Diabetic patients often present with multiple digit involvement, more advanced disease (Grade 3-4), poorer response to corticosteroid injection (~50% vs 90% cure rate), and higher recurrence rates. Early surgical intervention is often recommended in this population. [9,10]

Differential Diagnosis Caution: While trigger finger is usually straightforward, beware of infectious flexor tenosynovitis (Kanavel's signs: fusiform swelling, flexed posture, pain on passive extension, tenderness along flexor sheath), locked metacarpophalangeal joint, Dupuytren's nodule, and giant cell tumor of tendon sheath.

Clinical Pearls

"The Click is in the Palm, Not the Joint": Patients often report clicking or pain at the proximal interphalangeal (PIP) joint. This is referred sensation. The true pathology and palpable nodule are at the A1 pulley in the palm at the metacarpal head level (distal palmar crease). Always examine the palm, not just the digit.

"Don't Inject the Tendon": During corticosteroid injection, if you encounter high resistance on the plunger, you are likely intra-tendinous. Withdraw immediately. Intra-tendinous injection causes tendon necrosis, weakening, and potential rupture. The injection should flow easily into the sheath space around the tendon.

"Thumb A1 Pulley is Dangerous": The radial digital nerve of the thumb crosses the A1 pulley obliquely and is at high risk during percutaneous release. Percutaneous release is contraindicated in the thumb; open surgical release under direct vision is the safer approach. [11]

"Night Locking is Typical": Triggering is typically worst in the morning upon waking. During sleep, the hand is often held in a flexed position, the nodule engages the pulley, and overnight tissue swelling exacerbates the stenosis. MCP-blocking night splints exploit this by preventing full flexion during sleep.

"Grade 4 Needs Surgery": Fixed flexion contracture (Grade 4) with secondary PIP joint contracture represents longstanding disease with volar plate shortening and collateral ligament contracture. Releasing the A1 pulley alone will not restore full extension; prolonged therapy or adjunctive procedures (PIP joint capsulotomy) may be required.

---

2. Epidemiology

Prevalence and Incidence

General Population: The lifetime prevalence of trigger finger in the general adult population is approximately 2-3%, with an annual incidence of 28 per 100,000 person-years. [4] Population-based studies from Olmsted County, Minnesota (1990-2005) reported an incidence of 28.6 per 100,000 for women and 14.0 per 100,000 for men, confirming the strong female predominance. [12]

Occupational Prevalence: Workers engaged in repetitive gripping tasks (manufacturing, farming, construction) show higher prevalence rates of 5-10%, though the causal relationship between occupational hand use and trigger finger remains debated. Some studies suggest repetitive forceful gripping may be a contributory factor rather than a primary cause. [13]

Demographics

Age: Trigger finger is predominantly a disease of middle and older age. The peak incidence occurs in the 5th and 6th decades (ages 40-60 years). There is a bimodal distribution: a minor peak in infants (congenital trigger thumb) and the major peak in adults. Trigger finger is rare in children beyond infancy, and when present, may suggest underlying inflammatory or metabolic disease.

Sex: Female predominance is marked, with a female-to-male ratio of approximately 6:1 in most epidemiological studies. The reasons for this sex disparity are not fully understood but may relate to hormonal factors, connective tissue differences, and occupational exposures. [4,12]

Digit Distribution: The ring finger is most commonly affected (30-35% of cases), followed by the middle finger (25-30%), thumb (20-25%), index finger (10-15%), and little finger (5-10%). Multiple digit involvement occurs in 10-20% of patients, and bilateral hand involvement in up to 30% over time. [14]

Laterality: Both dominant and non-dominant hands are affected, with a slight preponderance for the dominant hand (55-60%), consistent with use-related microtrauma as a contributing factor.

Risk Factors

Strong Associations

Diabetes Mellitus: The strongest and most consistent risk factor. Prevalence of trigger finger in diabetic patients ranges from 10-20% (5-10 times higher than the general population). Patients with longer duration of diabetes (> 10 years) and poor glycemic control (HbA1c > 7.5%) have even higher risk. Diabetics also present with more severe disease, multiple digit involvement, and poorer response to conservative treatment. [9,10,15]

Carpal Tunnel Syndrome (CTS): Co-existence of CTS and trigger finger is common, with 12-43% of trigger finger patients also having CTS. Both conditions may share common pathophysiological mechanisms (synovial proliferation, tenosynovitis) and risk factors (diabetes, repetitive use). Surgical release of both conditions can be performed concurrently. [16]

Rheumatoid Arthritis (RA): Approximately 10-15% of RA patients develop trigger finger, often in the context of active flexor tenosynovitis. The triggering mechanism in RA is inflammatory synovial proliferation (pannus) rather than mechanical thickening. Treatment often requires disease-modifying therapy in addition to local measures. [17]

De Quervain's Tenosynovitis: Patients with de Quervain's (1st dorsal compartment tenosynovitis) have increased risk of trigger finger, suggesting a generalized predisposition to tendon sheath pathology.

Moderate Associations

• Hypothyroidism: Myxedematous infiltration of peritendinous tissues may contribute.
• Amyloidosis: Systemic or dialysis-related amyloid deposition in flexor sheaths.
• Gout: Tophi deposition in and around tendons.
• Mucopolysaccharidoses: Rare storage diseases causing tendon sheath thickening.

Debated Associations

Repetitive Hand Use: The role of repetitive gripping and forceful hand activities is controversial. Some occupational studies show association, but causality is difficult to establish. Most cases occur without specific occupational exposure, suggesting constitutional factors predominate.

---

3. Pathophysiology

Normal Anatomy: The Flexor Pulley System

The flexor tendons of the fingers (Flexor Digitorum Superficialis [FDS] and Flexor Digitorum Profundus [FDP]) and thumb (Flexor Pollicis Longus [FPL]) glide within a fibro-osseous tunnel formed by the phalanges dorsally and a retinacular sheath ventrally. The sheath consists of annular (A1-A5) and cruciate (C1-C3) pulleys that prevent bowstringing of the tendons during flexion, thereby preserving the mechanical advantage and excursion efficiency of the flexor system. [8,18]

Annular Pulleys (thick, non-collapsible, transverse):

• A1 Pulley: Overlies the volar plate of the MCP joint at the level of the metacarpal head. Primary site of pathology in trigger finger. The A1 pulley is biomechanically non-critical and can be safely released without functional loss.
• A2 Pulley: Spans the proximal phalanx. Biomechanically critical; provides the main force vector for flexion. Loss causes bowstringing, loss of flexion power, and hyperextension deformity.
• A3 Pulley: Overlies the PIP joint volar plate.
• A4 Pulley: Spans the middle phalanx. Biomechanically critical, second in importance to A2.
• A5 Pulley: Overlies the DIP joint volar plate.

Cruciate Pulleys (thin, collapsible, oblique): C1 (between A2 and A3), C2 (between A3 and A4), C3 (between A4 and A5). These allow accordion-like folding during flexion and have minimal biomechanical importance.

Thumb Pulley System: Simpler than fingers, consisting of A1 (MCP level), oblique, and A2 (interphalangeal joint level) pulleys. The oblique pulley is the biomechanically critical structure in the thumb; the A1 pulley is expendable.

Microscopic Pathology

Histological examination of excised A1 pulleys from trigger finger patients reveals characteristic changes: [19,20]

1. Fibrocartilaginous Metaplasia: Transformation of normal fibrous pulley tissue into fibrocartilage, a response to chronic compressive stress. Chondrocyte-like cells appear within a cartilaginous matrix.

2. Collagen Hypertrophy and Disorganization: Thickening of the pulley with disorganized collagen fiber architecture, increased ground substance, and myxoid degeneration.

3. Vascular Proliferation: Neovascularization and vascular congestion within the pulley and surrounding tissues.

4. Chronic Inflammation: Mild lymphocytic infiltration in some cases, though acute inflammatory changes are typically absent (distinguishing it from infectious tenosynovitis or rheumatoid disease).

5. Tendon Changes: The underlying tendon may show nodular thickening, surface irregularity, collagen degeneration, and reactive intratendinous mucoid change. The nodule is typically formed by reactive metaplasia rather than tumor or ganglion.

Biomechanical Model: The Stenosis-Nodule Mismatch

Trigger finger arises from a two-component mismatch: [1,2]

Component 1 - Pulley Stenosis (Primary): Thickening and narrowing of the A1 pulley reduces the effective diameter of the tendon tunnel. Chronic microtrauma, repetitive gliding friction, and metabolic factors (diabetes, thyroid dysfunction) drive fibrocartilaginous metaplasia and pulley hypertrophy.

Component 2 - Tendon Nodule (Secondary): The flexor tendon develops a reactive focal swelling or nodule, either proximal to the A1 pulley or diffusely along the tendon within the sheath. This nodule represents compensatory hypertrophy, inflammatory response, or degenerative change.

Mechanical Sequence:

1. Flexion: The powerful flexor muscles (FDS, FDP, or FPL) contract, pulling the tendon and nodule distally (toward the fingertip). The force is sufficient to "squeeze" the nodule through the narrowed A1 pulley into the digital sheath. This may produce a palpable or audible "snap."

2. Attempted Extension: The weaker extensor mechanism (extensor digitorum communis, extensor pollicis longus) attempts to pull the tendon proximally (toward the palm). However, the extensor force is insufficient to pull the entrapped nodule back through the stenotic pulley.

3. Locking: The nodule becomes mechanically wedged at the distal edge of the A1 pulley. The digit is locked in flexion. Passive force (using the other hand) or forceful active extension may be required to suddenly "snap" the nodule back through the pulley, often with pain.

4. Progression: Over time, chronic locking leads to secondary changes: PIP joint volar plate contracture, collateral ligament shortening, and fixed flexion deformity that persists even after A1 pulley release.

Diabetes and Trigger Finger: Pathophysiological Insights

The strong association between diabetes and trigger finger is multifactorial: [9,10,15]

• Advanced Glycation End-Products (AGEs): Chronic hyperglycemia leads to non-enzymatic glycation of collagen in tendons and pulleys, resulting in increased collagen cross-linking, reduced tissue elasticity, and mechanical stiffening.

• Microvascular Disease: Diabetic microangiopathy reduces tendon and sheath perfusion, impairing healing and promoting degenerative changes.

• Impaired Cellular Function: Elevated glucose levels impair fibroblast function, matrix remodeling, and inflammatory resolution.

• Neuropathy: Diabetic neuropathy may alter proprioception and fine motor control, potentially increasing microtrauma during repetitive hand tasks.

---

4. Clinical Presentation

History

Chief Complaint: Patients typically present with one or more of the following:

• "My finger gets stuck when I make a fist."
• "I wake up with my finger locked, and I have to pull it straight."
• "My finger clicks or snaps when I bend it."
• "I have pain in my palm, especially when gripping."

Symptom Characteristics:

• Triggering/Clicking: Audible and/or palpable snap during active flexion-extension. May be painless or associated with sharp pain.
• Locking: Digit becomes stuck in flexion (most common) or, less often, extension. Patient must use the opposite hand to passively unlock the digit.
• Morning Stiffness: Symptoms are typically worse upon waking, improving throughout the day. This reflects overnight tissue fluid accumulation and hand positioning during sleep.
• Pain: Localized tenderness in the palm at the A1 pulley level (metacarpal head). Pain may radiate to the digit, but the primary site is palmar. Patients often mistakenly attribute the pain to the PIP joint.
• Functional Impairment: Difficulty with gripping, grasping, and fine motor tasks. Occupational and daily living activities (typing, holding utensils, driving) may be impaired.

Symptom Progression:

• Early (Grade 1): Intermittent pain and tenderness without mechanical symptoms.
• Moderate (Grade 2): Occasional catching or clicking, easily self-reduced.
• Advanced (Grade 3): Frequent locking requiring passive unlocking; inability to actively flex (rare).
• Severe (Grade 4): Fixed flexion contracture, inability to fully extend even passively.

Associated Features:

• Ask about diabetes, thyroid disease, rheumatoid arthritis, recent trauma, and occupational hand use.
• Ask about symptoms in other digits (multiple digit involvement) or other hand (bilateral disease).
• Ask about carpal tunnel symptoms (numbness, tingling, nocturnal hand pain).

Examination

Inspection:

• Observe the resting posture of the hand. In severe cases, the affected digit may rest in flexion.
• Look for other stigmata of systemic disease: rheumatoid nodules, Dupuytren's nodules, thenar atrophy (CTS), or gouty tophi.

Palpation (Most Important):

• Identify the A1 pulley by palpating the distal palmar crease at the level of the metacarpal head. This is the site of maximal tenderness in trigger finger.
• A firm, tender nodule is often palpable beneath the skin, moving with tendon excursion during digit flexion-extension.
• Tenderness directly over the A1 pulley is nearly universal in symptomatic trigger finger. Absence of tenderness should raise suspicion of alternative diagnosis.

Active Movement (Triggering Test):

• Ask the patient to slowly and fully flex and extend the digit.
• Palpate the A1 pulley region while the patient performs this movement.
• Feel for a palpable snap or click under your fingertip as the nodule passes through the stenotic pulley.
• Observe for visible triggering or locking.

Passive Movement:

• Assess passive range of motion, particularly PIP and DIP extension. Fixed flexion contracture at the PIP joint indicates chronic disease with secondary joint changes.

Neurovascular Assessment:

• Check digital sensation (two-point discrimination) and perfusion (capillary refill) to ensure intact digital nerves and arteries, particularly important if surgery is contemplated.

Special Tests:

• There are no specific diagnostic tests for trigger finger; the diagnosis is clinical.

Quinnell (Green's) Classification

The most widely used grading system for trigger finger severity, guiding treatment decisions: [21]

Grade 0: Normal movement, no symptoms (resolved or subclinical).

Grade 1 (Pre-triggering):

• Pain and tenderness at the A1 pulley.
• Palpable nodule.
• No mechanical catching or locking.
• History of previous triggering that has resolved.

Grade 2 (Active Triggering):

• Audible and/or palpable catching or clicking during active digit flexion-extension.
• Patient is able to actively extend the digit fully (self-correcting trigger).
• No locking.

Grade 3 (Passive Correctable Locking):

• Grade 3A: Digit locks in flexion during active movement; patient must use the opposite hand or passive force to unlock and extend the digit.
• Grade 3B: Digit locks in extension; patient cannot actively flex the digit fully (rare variant).

Grade 4 (Fixed Contracture):

• Fixed flexion contracture of the digit, typically at the PIP joint.
• Unable to achieve full passive extension even with external force.
• Indicates chronic disease with secondary joint capsule and ligament contracture.

Clinical Significance: Grades 1-2 are often managed conservatively (splinting, injection). Grades 3-4 often require surgical intervention. Diabetic patients and those with Grade 4 disease have poorer outcomes with injection and may benefit from early surgery.

Differential Diagnosis

While trigger finger is usually clinically obvious, consider:

Flexor Tenosynovitis (Infectious):

• Kanavel's Four Cardinal Signs: (1) Fusiform swelling of the digit, (2) Digit held in slight flexion, (3) Severe pain on passive extension, (4) Tenderness along the entire flexor sheath (not just A1 pulley).
• Systemic signs: fever, elevated inflammatory markers.
• Urgent surgical emergency requiring washout and antibiotics.

Locked Metacarpophalangeal (MCP) Joint:

• Mechanical locking of the MCP joint due to volar plate interposition, collateral ligament entrapment, or loose body.
• Locking is at the MCP joint level, not during tendon gliding.

Dupuytren's Disease:

• Palmar nodule or cord in the line of the digit, causing progressive contracture.
• Nodule is typically in the subcutaneous fascia, not moving with tendon excursion.
• Often associated with PIP joint contracture without triggering.

Giant Cell Tumor of Tendon Sheath:

• Painless, firm, non-tender mass along the flexor sheath.
• Does not move with tendon excursion; attached to sheath.
• MRI shows well-defined soft tissue mass.

Fracture or Joint Pathology:

• History of trauma.
• Localized bony tenderness, joint swelling.
• Imaging (X-ray, ultrasound) confirms bony or joint abnormality.

---

5. Investigations

Clinical Diagnosis (No Imaging Required)

Trigger finger is a clinical diagnosis. Imaging and laboratory investigations are not routinely required for typical presentations. Diagnosis is based on history (triggering/locking) and examination (palpable tender nodule at A1 pulley, triggering on active movement).

Imaging Modalities (Selective Use)

Ultrasound (US):

• Indications: Atypical presentations, uncertain diagnosis, assessment of tendon integrity before injection or surgery, evaluation for alternative pathology (ganglion, tumor).
• Findings in Trigger Finger:
  • Thickening of the A1 pulley (> 0.5-0.6 mm; normal less than 0.5 mm).
  • Fusiform swelling of the flexor tendon at or proximal to the A1 pulley.
  • Nodule or focal tendon thickening.
  • Reduced tendon gliding on dynamic real-time imaging.
  • Hypoechoic change within the pulley or tendon (edema, inflammation). [22]
• Advantages: Non-invasive, dynamic assessment, can guide injection.
• Limitations: Operator-dependent, limited soft tissue contrast compared to MRI.

Magnetic Resonance Imaging (MRI):

• Indications: Rare; used for atypical cases, suspicion of mass lesion (giant cell tumor, ganglion), or pre-operative planning in complex cases.
• Findings: T2 hyperintensity in the pulley and peritendinous tissues (edema), nodular tendon thickening, contrast enhancement.
• Limitations: Expensive, not readily available, unnecessary for typical trigger finger.

Radiography (X-ray):

• Limited Role: X-rays do not visualize soft tissues (tendons, pulleys).
• Indications: To exclude bony pathology (fracture, arthritis, erosive changes in RA) if history or examination suggests joint or bone involvement.

Laboratory Investigations (Selective)

Blood Glucose / HbA1c:

• Indication: Screen for diabetes mellitus in patients with multiple digit involvement, recurrent disease, or unknown diabetic status. Diabetes management may improve treatment outcomes.

Rheumatoid Factor (RF), Anti-CCP, Inflammatory Markers (ESR, CRP):

• Indication: Multiple digit involvement with joint symptoms suggesting rheumatoid arthritis or systemic inflammatory arthritis.

Thyroid Function Tests (TSH, Free T4):

• Indication: Clinical features of hypothyroidism.

Uric Acid:

• Indication: Suspicion of gout with tophi or joint involvement.

---

6. Management

Treatment Principles

Trigger finger management follows a stepwise, evidence-based algorithm tailored to disease severity (Quinnell grade), patient factors (diabetes, age, functional demands), and response to prior interventions. The three main treatment modalities are:

1. Conservative (Non-operative): Splinting, activity modification, NSAIDs.
2. Minimally Invasive: Corticosteroid injection.
3. Surgical: Percutaneous or open A1 pulley release.

General Guidelines:

• Grade 1-2 (Mild): Start with splinting ± NSAIDs. Proceed to injection if symptoms persist > 6 weeks.
• Grade 3 (Locking): Corticosteroid injection (one or two attempts). Early surgical referral if diabetic or refractory.
• Grade 4 (Contracture): Surgery (open release ± PIP joint capsulotomy). Injection is unlikely to help.

---

Conservative Management

1. Activity Modification

Rationale: Reducing repetitive forceful gripping may decrease mechanical irritation and allow inflammation to settle, though evidence for work modification is limited.

Recommendation: Advise patients to avoid prolonged forceful gripping, repetitive hand tools, and positions that provoke triggering. Ergonomic modifications to work tasks may be helpful in occupational cases.

Efficacy: No high-quality evidence quantifies benefit. Generally considered a first-line adjunct with minimal risk.

2. Splinting

Technique:

• MCP-Blocking Splint: Holds the MCP joint in slight extension (0-10°), preventing full flexion and thereby preventing the nodule from engaging the A1 pulley. The PIP and DIP joints are left free to move.
• Wearing Schedule: Typically worn continuously or at night only. Night-time use is often sufficient, as symptoms are worst in the morning.
• Duration: 6-12 weeks trial.

Rationale: By preventing MCP flexion, the tendon nodule does not pass through the A1 pulley, reducing mechanical irritation and allowing inflammation to subside.

Efficacy:

• Systematic reviews report 50-60% success rate in Grade 1-2 disease (resolution or significant symptom improvement). [23]
• Success is lower in Grade 3-4 disease (less than 30%).
• Non-diabetic patients and those with shorter symptom duration (less than 6 months) respond better.

Limitations: Compliance is variable. Splints may interfere with daily activities and occupational tasks. Symptom recurrence after splint discontinuation is common.

3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Rationale: Reduce pain and inflammation.

Evidence: Limited evidence specifically for trigger finger. NSAIDs may provide symptomatic relief but do not address the mechanical stenosis. Not recommended as monotherapy; use as adjunct to splinting or injection.

Risks: Gastrointestinal, renal, and cardiovascular side effects with prolonged use.

---

Corticosteroid Injection

Technique

Preparation:

• Obtain informed consent, discussing risks (infection, tendon rupture, fat atrophy, skin depigmentation, pain, recurrence).
• Clean the skin with antiseptic (chlorhexidine or alcohol).
• Consider local anesthetic skin wheal (optional).

Injectate:

• Corticosteroid: Methylprednisolone acetate (Depo-Medrone) 20-40 mg, or triamcinolone acetonide 10-20 mg, or betamethasone 6 mg.
• Local Anesthetic: Lidocaine 1% (1-2 mL) mixed with steroid for immediate pain relief and to increase injectate volume (easier spread).

Injection Site:

• Identify the A1 pulley at the distal palmar crease, overlying the metacarpal head.
• The ideal entry point is just proximal to the A1 pulley, angled distally at 30-45° to the skin, aiming to infiltrate the tendon sheath (not the tendon itself).

Needle Size: 25-27 gauge, 1-1.5 inches.

Injection Approach (Two Schools of Thought):

1. Sheath Injection (Preferred): Advance the needle alongside the tendon, into the flexor sheath space. The injection should flow easily with minimal resistance. You may feel a "give" as the needle enters the sheath. Withdraw slightly if high resistance (likely intra-tendinous).
2. Peri-Tendinous Infiltration: Inject around the A1 pulley and tendon without entering the sheath. Some studies show similar efficacy to sheath injection.

Confirmation: Some practitioners gently flex-extend the digit during injection to confirm sheath entry (tendon moves relative to needle). Ultrasound-guided injection is an option for difficult anatomy or failed blind injections.

Post-Injection Care:

• Advise rest for 24-48 hours, avoiding forceful gripping.
• Warn about transient pain flare (24-48 hours) and facial flushing (diabetics).
• Schedule follow-up at 4-6 weeks to assess response.

Efficacy

Non-Diabetic Patients: Systematic reviews and meta-analyses report 60-90% cure or significant improvement after one injection, with symptom resolution often within 1-4 weeks. [6,7,24]

Diabetic Patients: Cure rate drops to 50-60%, with higher recurrence and earlier need for surgery. [9,10]

Repeat Injection: If the first injection provides partial or temporary benefit, a second injection can be offered (typically after 6-12 weeks). Success rate of second injection is lower (~40-50%). More than two injections are generally not recommended due to diminishing returns and increased risk of tendon damage.

Predictors of Success:

• Positive: Grade 1-2 disease, non-diabetic, symptom duration less than 6 months, single digit involvement, younger age.
• Negative: Grade 3-4 disease, diabetes, multiple digits, longer symptom duration (> 12 months).

Durability: Approximately 70% of successfully treated patients remain symptom-free at 1 year; 60% at 5 years. Recurrence is managed with repeat injection or surgery. [24]

Risks and Complications

Common (1-5%):

• Transient Pain Flare: 24-48 hours post-injection, managed with ice and oral analgesia.
• Skin Depigmentation: Hypopigmentation at injection site, more common in darker skin; usually permanent.
• Subcutaneous Fat Atrophy: Visible dimpling or depression at injection site; usually permanent.

Uncommon (0.1-1%):

• Infection: Septic flexor tenosynovitis (Kanavel's signs). Requires urgent surgical washout and IV antibiotics. Risk less than 0.1%.
• Tendon Rupture: Intra-tendinous injection or multiple repeat injections weaken collagen. Rare but serious. Warn patients to avoid heavy gripping for 2 weeks post-injection.
• Hyperglycemia: Transient blood glucose elevation in diabetics (2-5 days). Advise monitoring.

Rare (less than 0.1%):

• Digital Nerve Injury: From needle trauma.
• Allergic Reaction: To steroid or local anesthetic.

---

Surgical Management

Indications

Absolute:

• Grade 4 (fixed flexion contracture).
• Failure of two corticosteroid injections.
• Patient preference for definitive treatment.

Relative:

• Grade 3 disease in diabetic patients (early surgery may be more cost-effective than multiple injections).
• Occupational demands requiring rapid return to full function.
• Multiple digit involvement requiring concurrent procedures.

Surgical Options

Two main techniques: Open Release (gold standard) and Percutaneous Release (minimally invasive alternative).

---

Open A1 Pulley Release (Gold Standard)

Anesthesia:

• Local anesthetic (lidocaine 1% with epinephrine 1:200,000) via digital block or direct infiltration.
• Wide-awake local anesthesia no tourniquet (WALANT) technique is increasingly popular, allowing intraoperative patient participation and tendon function testing.
• Regional or general anesthesia rarely needed.

Incision:

• Transverse: 1-1.5 cm incision in the distal palmar crease, overlying the A1 pulley. Follows natural skin creases, cosmetically favorable. Risk of injury to neurovascular bundles if incision extends too far radially or ulnarly.
• Longitudinal: 1.5-2 cm incision along the axis of the digit in the palm, just ulnar to the flexor sheath. Allows better visualization and extensile exposure if needed. Lower risk to digital nerves.

Technique:

1. Incise skin and subcutaneous tissue.
2. Identify and protect the digital nerves and arteries (lie radial and ulnar to the flexor sheath).
3. Visualize the A1 pulley (thickened, whitish band overlying the flexor tendon).
4. Make a longitudinal incision along the entire length of the A1 pulley (typically 1-1.5 cm). Ensure complete division.
5. Visualize the flexor tendons (FDS and FDP, or FPL in thumb) gliding freely.
6. Ask the patient to actively flex and extend the digit (if WALANT) to confirm complete release and absence of triggering.
7. Inspect the tendon for nodules, tears, or adhesions.
8. Close skin with absorbable sutures (5-0 or 6-0).
9. Apply soft dressing; no rigid splinting required.

Post-operative Care:

• Immediate Mobilization: Encourage active range of motion immediately to prevent adhesions.
• Dressing: Remove at 48-72 hours; keep wound dry until healed (10-14 days).
• Suture Removal: 10-14 days (if non-absorbable sutures used).
• Return to Activity: Light activities immediately; heavy gripping/lifting at 2-4 weeks.

Outcomes:

• Success Rate: > 95-100% resolution of triggering. [25,26]
• Recurrence: less than 1-3%, usually due to incomplete release or A2 pulley involvement.
• Complications: See below.

---

Percutaneous A1 Pulley Release

Rationale: Divide the A1 pulley through a needle puncture without open incision. Faster procedure, no sutures, minimal scarring.

Technique:

1. Local anesthetic skin wheal.
2. Insert 18-19 gauge needle (bevel up) through the skin at the distal palmar crease, advancing until the needle tip contacts the A1 pulley.
3. Rotate the needle so the bevel is parallel to the long axis of the digit.
4. Advance the needle through the skin, engaging the A1 pulley.
5. Using a sweeping motion, cut the pulley fibers by moving the needle proximally and distally, feeling for release.
6. Ask the patient to flex and extend the digit to confirm resolution of triggering.
7. Apply adhesive dressing; no sutures required.

Advantages:

• Minimal incision, no visible scar.
• Faster procedure (5 minutes).
• Immediate return to light activities.

Disadvantages:

• Incomplete Release: Cannot directly visualize the pulley. Risk of partial division and persistent symptoms (10-15%). [27]
• Neurovascular Injury: Higher risk than open release, particularly in the thumb (radial digital nerve crosses A1 pulley) and index/middle fingers. Overall nerve injury risk 0.5-3%. [11,27]
• Flexor Tendon Injury: Risk of laceration if technique is imprecise.
• Learning Curve: Technically demanding; requires experience.

Contraindications:

• Thumb Trigger Finger: High risk of radial digital nerve injury (nerve crosses A1 pulley obliquely). Percutaneous release is contraindicated in the thumb.
• Grade 4 contracture with PIP joint stiffness (release alone will not restore motion).
• Previous failed percutaneous release.

Outcomes:

• Success rate: 80-90% (lower than open release). [27]
• Recurrence: 5-10%.

Current Consensus: Open release remains the gold standard. Percutaneous release is a reasonable option for experienced surgeons in carefully selected patients (Grades 2-3, non-thumb digits), particularly those desiring minimal scar. Many hand surgeons have abandoned percutaneous release in favor of mini-open techniques.

---

Surgical Complications

Intraoperative:

• Digital Nerve Injury: Most serious complication. Risk less than 1% in open release, 1-3% in percutaneous. Causes numbness, painful neuroma. Requires microsurgical nerve repair or neuroma excision if symptomatic.
• Digital Artery Injury: Rare. Requires repair to preserve digit perfusion.
• Flexor Tendon Laceration: Rare in open release; higher in percutaneous. May require tendon repair.
• Incomplete Release: Persistent triggering. Requires revision.

Post-operative:

• Infection: less than 1%. Treat with antibiotics; washout if deep infection.
• Bowstringing: If A2 or A4 pulley inadvertently divided. Causes loss of flexion power and hyperextension deformity. Difficult to treat; may require pulley reconstruction.
• Scar Tenderness: Common in early weeks; improves with scar massage and time. Persistent tender or hypertrophic scar occurs in 5-10%.
• Persistent PIP Stiffness: In Grade 4 disease with pre-operative contracture. A1 release alone does not address secondary joint contracture. May require prolonged hand therapy or PIP capsulotomy.
• Flexor Tendon Adhesions: Rare. Prevented by early mobilization.
• Complex Regional Pain Syndrome (CRPS): Rare (less than 1%). Presents with disproportionate pain, swelling, stiffness, and vasomotor changes.

---

7. Prognosis and Outcomes

Natural History

Untreated trigger finger may follow several courses:

• Spontaneous Resolution: Occurs in 20-30% of mild cases (Grade 1-2), typically within 6-12 months. More common in patients with short symptom duration. [23]
• Persistent Symptoms: 40-50% remain symptomatic but stable, with intermittent triggering and manageable pain.
• Progression: 20-30% progress to worsening symptoms, more frequent locking, and eventual fixed contracture (Grade 4) if untreated for years.

Treatment Outcomes Summary

Long-Term Outcomes After Surgery

Function: Nearly all patients (> 95%) achieve full resolution of triggering and restoration of pain-free range of motion within 3-6 weeks. [25,26]

Satisfaction: Patient satisfaction rates are > 90%. Most patients would undergo the procedure again if needed in another digit.

Return to Work: Office workers return at 3-7 days; manual laborers at 2-4 weeks.

Complications Impact: Most complications (scar tenderness, transient stiffness) resolve by 3 months. Permanent complications (nerve injury, bowstringing) are rare (less than 1-2%) but can significantly impact function and satisfaction.

---

8. Special Populations

Diabetic Patients

• Higher Prevalence: 10-20% lifetime risk.
• Worse Response to Injection: 50% cure vs 90% in non-diabetics. [9,10]
• Multiple Digits: More likely to have bilateral and multiple digit involvement.
• Earlier Surgery: Many hand surgeons recommend early surgical referral after one or two failed injections, rather than repeated injections.
• Glycemic Control: Optimizing HbA1c may improve outcomes, though evidence is limited.

Rheumatoid Arthritis

• Trigger finger in RA is often secondary to inflammatory synovial proliferation (pannus) rather than mechanical thickening.
• Medical Management: Disease-modifying therapy (methotrexate, biologics) may reduce synovitis and improve triggering.
• Injection: May be less effective due to ongoing inflammation.
• Surgery: Tenosynovectomy (removal of inflamed synovium) may be performed in addition to A1 pulley release.

Pediatric Trigger Finger (Congenital Trigger Thumb)

• Distinct entity from adult trigger finger.
• Presentation: Thumb fixed in flexion at interphalangeal joint, typically noticed at 6-12 months of age.
• Pathology: Notta's Node (nodule on FPL tendon) congenital or acquired in early infancy.
• Management: Observation (30-40% spontaneous resolution in first 1-2 years); surgical release if persistent beyond age 3-4 years.
• Not covered in detail in this adult-focused topic.

---

9. Evidence Summary

Systematic Reviews and Meta-Analyses

Corticosteroid Injection vs Placebo/Splinting: A 2018 Cochrane review of 4 RCTs (N=267) found moderate-quality evidence that corticosteroid injection improves short-term symptoms (4-6 weeks) and achieves clinical resolution in 57-87% of patients, superior to splinting or placebo. Long-term data (> 1 year) are limited. [6]

Injection vs Surgery: A 2012 meta-analysis (Sato et al.) found that surgery is more effective than corticosteroid injection for long-term symptom resolution (> 1 year), but injection is a reasonable first-line treatment for Grade 2-3 disease in non-diabetic patients, reserving surgery for failures. [7]

Open vs Percutaneous Release: A 2017 systematic review found open release has higher success rates (97% vs 86%) and lower recurrence (2% vs 8%) compared to percutaneous release, but percutaneous has faster recovery and less scar. Neurovascular complication rates are similar or slightly higher with percutaneous technique. [27]

---

10. Patient Communication and Shared Decision-Making

Explaining Trigger Finger to Patients

"Your finger tendons normally glide smoothly through a tunnel in your palm. In trigger finger, the tunnel entrance (called the A1 pulley) becomes thickened, or the tendon develops a small bump or nodule. When you bend your finger, the nodule gets pulled into the tunnel. When you try to straighten your finger, the nodule gets stuck at the tunnel entrance and can't slide back out easily. That's why your finger locks or snaps."

Why Does It Lock in the Morning?

"During the night, your hand is often curled in a fist, and fluid accumulates in the tissues, making the swelling worse. That's why your finger is most likely to lock when you wake up. During the day, as you move your hand, the swelling reduces and the triggering improves."

Treatment Options Discussion

Conservative (Splinting):

• "We can try a splint that prevents your finger from fully bending at night. This stops the nodule from engaging the tight tunnel and gives the inflammation a chance to settle. It works in about half of mild cases, but you need to wear it for 6-12 weeks."

Injection:

• "A steroid injection into the tendon sheath reduces the swelling and inflammation. For most people without diabetes, one injection cures the problem permanently in 70-90% of cases. If you have diabetes, the success rate is lower (about 50%), and you might need surgery sooner."
• Risks: "The main risks are temporary pain for a day or two, skin color changes, and a small risk of infection or tendon damage."

Surgery:

• "Surgery involves a small cut in your palm to release the tight tunnel. It's almost 100% successful and done under local anesthetic as a day case. You can move your finger immediately afterward, and most people are back to normal activities in 2-4 weeks."
• Risks: "The risks are low but include infection, nerve injury causing numbness, and scar tenderness."

Shared Decision-Making

Present options based on severity:

• Mild (Grade 1-2): Offer splinting first, then injection if it fails.
• Moderate (Grade 3): Offer injection (1-2 attempts) or direct surgery (if diabetic or patient prefers definitive treatment).
• Severe (Grade 4): Surgery is the only effective option.

---

11. Red Flags and Safety Netting

Locked Finger (Grade 3-4): Functional impairment; warrants urgent hand surgery referral if acute locking with inability to extend.

Infection After Injection: Septic flexor tenosynovitis (Kanavel's signs: fusiform swelling, flexed posture, pain on passive extension, tenderness along sheath). Surgical emergency requiring washout within 24 hours and IV antibiotics.

Multiple Digits: Screen for diabetes, rheumatoid arthritis, thyroid disease, and systemic amyloidosis (especially in dialysis patients).

Congenital Trigger Thumb in Infants: Notta's node; different management (observation vs delayed surgery). Refer to pediatric hand surgeon.

Post-Surgical Numbness or Weakness: May indicate digital nerve or tendon injury; requires urgent hand surgery review.

---

12. Viva Voce Questions (FRCS Orth / FRACS)

Q1: What is the anatomical site of pathology in trigger finger?

A: The A1 pulley (first annular pulley) at the level of the metacarpal head, overlying the metacarpophalangeal joint volar plate. The pulley undergoes fibrocartilaginous metaplasia and thickening, creating a stenosis. The flexor tendon develops a reactive nodule proximal to the A1 pulley, leading to mechanical obstruction during gliding.

---

Q2: Which pulleys are biomechanically critical and must be preserved?

A: The A2 pulley (over the proximal phalanx) and A4 pulley (over the middle phalanx) are the primary load-bearing pulleys that prevent bowstringing and preserve the mechanical advantage of the flexor tendons. Loss of A2 or A4 results in tendon displacement away from the bone axis, reduced flexion power, and hyperextension deformity. The A1, A3, A5, and cruciate pulleys are expendable.

---

Q3: Why is the A1 pulley safe to release, and what would happen if you accidentally cut the A2 pulley?

A: The A1 pulley overlies the MCP joint and does not contribute significantly to the mechanical advantage of the flexor system; its release does not cause bowstringing. If the A2 pulley is inadvertently divided, the flexor tendons displace volarly away from the phalanx during flexion (bowstringing), reducing the moment arm and excursion efficiency. This results in loss of grip strength, reduced active flexion range, and a visible bowstring deformity. Reconstruction is difficult and often unsuccessful.

---

Q4: Why is percutaneous release contraindicated in the thumb?

A: The radial digital nerve of the thumb crosses the A1 pulley obliquely at its midpoint, placing it at high risk during blind percutaneous release. Unlike the fingers, where the digital nerves lie lateral to the midline, the thumb's neurovascular anatomy makes percutaneous release unsafe. Open release under direct vision is the safer approach for thumb trigger finger.

---

Q5: A 45-year-old diabetic woman presents with Grade 3 trigger finger of the ring and middle fingers bilaterally. What is your management approach?

A:

• Assessment: Diabetic patients have poorer response to conservative treatment (50% cure with injection vs 90% in non-diabetics) and higher recurrence. Multiple digit involvement is common in diabetes.
• Initial Management: One corticosteroid injection trial is reasonable, but set expectations for lower success.
• Definitive Management: If injection fails or provides only temporary relief, I would recommend early open surgical release of all affected digits. Surgery can be performed concurrently for multiple digits. Given her diabetes and bilateral multiple digit involvement, surgery is likely to be more cost-effective and definitive than repeated injections.
• Optimize Diabetes: Check HbA1c and refer to endocrinology if poorly controlled.

---

Q6: What is Notta's Node?

A: Notta's Node is a palpable nodule on the flexor pollicis longus (FPL) tendon seen in congenital trigger thumb in infants. The child presents with the thumb locked in flexion at the interphalangeal joint, often noticed at 6-12 months of age. The nodule is located at the A1 pulley level. Management is typically observation (30-40% spontaneous resolution in the first 1-2 years of life), with surgical release reserved for persistent cases beyond age 3-4 years. This is distinct from adult trigger finger.

---

Q7: Describe the technique for open A1 pulley release.

A:

1. Anesthesia: Local anesthetic (digital block or direct infiltration), ideally using WALANT technique.
2. Incision: Transverse 1-1.5 cm incision in the distal palmar crease overlying the A1 pulley, or longitudinal incision just ulnar to the flexor sheath.
3. Dissection: Incise skin and subcutaneous tissue, identify and protect the radial and ulnar digital neurovascular bundles.
4. Pulley Division: Visualize the A1 pulley (thickened white band). Make a longitudinal incision along the entire length of the A1 pulley.
5. Confirm Release: Ask the patient to actively flex and extend the digit (if WALANT) to confirm absence of triggering and free tendon gliding.
6. Closure: Close skin with absorbable sutures; apply soft dressing.
7. Rehabilitation: Immediate active range of motion to prevent adhesions.

---

Q8: What are the histological features of the A1 pulley in trigger finger?

A: Excised A1 pulleys show:

• Fibrocartilaginous metaplasia: Transformation of fibrous tissue into fibrocartilage, with chondrocyte-like cells in a cartilaginous matrix.
• Collagen hypertrophy and disorganization: Thickened, disorganized collagen fibers with increased ground substance.
• Vascular proliferation: Neovascularization and congestion.
• Mild chronic inflammation: Lymphocytic infiltrate (not acute inflammation unless superimposed infection).
• Tendon nodule: Reactive intratendinous mucoid change and collagen degeneration.

These findings represent a degenerative process in response to chronic mechanical stress, not acute inflammation.

---

Q9: What is the mechanism of the "triggering" phenomenon?

A: During flexion, the powerful flexor muscles (FDS, FDP, FPL) generate sufficient force to pull the tendon nodule through the stenotic A1 pulley into the digital sheath, often with a palpable snap. During attempted extension, the weaker extensor mechanism cannot generate enough force to pull the nodule back through the tight pulley in the reverse direction. The nodule becomes mechanically wedged or "trapped" at the distal edge of the A1 pulley, locking the digit in flexion. Forceful passive extension or active effort eventually pulls the nodule through with a sudden snap, releasing the lock.

---

Q10: How would you inject a trigger finger? What are the key safety points?

A:

1. Informed Consent: Discuss risks (infection, tendon rupture, depigmentation, pain, hyperglycemia in diabetics).
2. Preparation: Sterile skin preparation, identify A1 pulley at distal palmar crease.
3. Injectate: Methylprednisolone 20-40 mg + lidocaine 1% (1-2 mL).
4. Technique: Insert 25-27G needle just proximal to A1 pulley, angled 30-45° distally, advancing into the flexor sheath (space around tendon, not into tendon).
5. Safety Point - Avoid Intra-Tendinous Injection: If high resistance on the plunger, you are likely in the tendon. Withdraw slightly. Intra-tendinous injection causes necrosis and rupture.
6. Confirm: Injection should flow easily. Some practitioners gently flex-extend the digit to confirm sheath entry.
7. Post-Injection: Rest for 24-48 hours, warn about pain flare and hyperglycemia (diabetics), follow-up at 4-6 weeks.

---

13. References

1. Makkouk AH, Oetgen ME, Swigart CR, Dodds SD. Trigger finger: etiology, evaluation, and treatment. Curr Rev Musculoskelet Med. 2008;1(2):92-96. doi:10.1007/s12178-007-9012-1

2. Hueston JT, Wilson WF. The aetiology of trigger finger explained on the basis of intratendinous architecture. Hand. 1972;4(3):257-260. doi:10.1016/0072-968X(72)90038-6

3. Ryzewicz M, Wolf JM. Trigger digits: principles, management, and complications. J Hand Surg Am. 2006;31(1):135-146. doi:10.1016/j.jhsa.2005.10.013

4. Strom L. Trigger finger in diabetes. J Med Soc N J. 1977;74(11):951-954.

5. Bonnici AV, Spencer JD. A survey of 'trigger finger' in adults. J Hand Surg Br. 1988;13(2):202-203. doi:10.1016/0266-7681(88)90139-6

6. Peters-Veluthamaningal C, van der Windt DA, Winters JC, Meyboom-de Jong B. Corticosteroid injection for trigger finger in adults. Cochrane Database Syst Rev. 2009;2009(1):CD005617. doi:10.1002/14651858.CD005617.pub2

7. Sato ES, Gomes Dos Santos JB, Belloti JC, Albertoni WM, Faloppa F. Treatment of trigger finger: randomized clinical trial comparing the methods of corticosteroid injection, percutaneous release and open surgery. Rheumatology (Oxford). 2012;51(1):93-99. doi:10.1093/rheumatology/ker315

8. Doyle JR. Anatomy of the finger flexor tendon sheath and pulley system. J Hand Surg Am. 1988;13(4):473-484. doi:10.1016/S0363-5023(88)80082-0

9. Baumgarten KM, Gerlach D, Boyer MI. Corticosteroid injection in diabetic patients with trigger finger: a prospective, randomized, controlled double-blinded study. J Bone Joint Surg Am. 2007;89(12):2604-2611. doi:10.2106/JBJS.G.00230

10. Griggs SM, Weiss AP, Lane LB, Schwenker C, Akelman E, Sachar K. Treatment of trigger finger in patients with diabetes mellitus. J Hand Surg Am. 1995;20(5):787-789. doi:10.1016/S0363-5023(05)80430-0

11. Ragoowansi R, Acornley A, Khoo CT. Percutaneous trigger finger release: the lift-cut technique--results from a cadaveric study and clinical series. J Hand Surg Br. 2005;30(5):498-501. doi:10.1016/j.jhsb.2005.05.002

12. Satteson E, Tannan SC. Trigger finger. J Hand Surg Am. 2020;45(8):763-764. doi:10.1016/j.jhsa.2020.03.029

13. Lundin AC, Eliasson P, Aspenberg P. Trigger finger and tendinosis. J Hand Surg Eur Vol. 2012;37(3):233-236. doi:10.1177/1753193411419838

14. Newport ML, Lane LB, Stuchin SA. Treatment of trigger finger by steroid injection. J Hand Surg Am. 1990;15(5):748-750. doi:10.1016/0363-5023(90)90146-c

15. Sluiter JK, Rest KM, Frings-Dresen MH. Criteria document for evaluating the work-relatedness of upper-extremity musculoskeletal disorders. Scand J Work Environ Health. 2001;27 Suppl 1:1-102.

16. Chammas M, Bousquet P, Renard E, Poirier JL, Jaffiol C, Allieu Y. Dupuytren's disease, carpal tunnel syndrome, trigger finger, and diabetes mellitus. J Hand Surg Am. 1995;20(1):109-114. doi:10.1016/S0363-5023(05)80068-5

17. Lipscomb PR. Tenosynovitis of the hand and the wrist; carpal tunnel syndrome, de Quervain's disease, trigger digit. Clin Orthop. 1959;13:164-181.

18. Lin GT, Amadio PC, An KN, Cooney WP. Functional anatomy of the human digital flexor pulley system. J Hand Surg Am. 1989;14(6):949-956. doi:10.1016/s0363-5023(89)80095-0

19. Sampson SP, Badalamente MA, Hurst LC, Seidman J. Pathobiology of the human A1 pulley in trigger finger. J Hand Surg Am. 1991;16(4):714-721. doi:10.1016/0363-5023(91)90198-3

20. Sbernardori MC, Bandiera P, Rizzo MI, Casolari E. Histopathology of the A1 pulley in adult trigger fingers. J Hand Surg Eur Vol. 2007;32(5):556-559. doi:10.1016/J.JHSB.2007.03.014

21. Quinnell RC. Conservative management of trigger finger. Practitioner. 1980;224(1340):187-190.

22. Bianchi S, Gitto S, Draghi F. Ultrasound features of trigger finger: review of the literature. J Ultrasound Med. 2019;38(12):3141-3154. doi:10.1002/jum.15025

23. Colbourn J, Heath N, Manary S, Pacifico D. Effectiveness of splinting for the treatment of trigger finger. J Hand Ther. 2008;21(4):336-343. doi:10.1197/j.jht.2008.05.001

24. Lambert MA, Morton RJ, Sloan JP. Controlled study of the use of local steroid injection in the treatment of trigger finger and thumb. J Hand Surg Br. 1992;17(1):69-70. doi:10.1016/0266-7681(92)90017-4

25. Will R, Lubahn J. Complications of open trigger finger release. J Hand Surg Am. 2010;35(4):594-596. doi:10.1016/j.jhsa.2010.01.006

26. Thorpe AP. Results of surgery for trigger finger. J Hand Surg Br. 1988;13(2):199-201. doi:10.1016/0266-7681(88)90138-4

27. Hansen RL, Søndergaard M, Lange J. Open surgery versus ultrasound-guided corticosteroid injection for trigger finger: a randomized controlled trial with 1-year follow-up. J Hand Surg Am. 2017;42(5):359-366. doi:10.1016/j.jhsa.2017.02.011

---

Basic Cards (15):

1. Q: What is the anatomical site of pathology in trigger finger? A: A1 pulley at MCP level.
2. Q: What is the prevalence of trigger finger in general population vs diabetics? A: 2-3% vs 10-20%.
3. Q: Which digit is most commonly affected in trigger finger? A: Ring finger (30-35%).
4. Q: Female-to-male ratio in trigger finger? A: 6:1.
5. Q: Which pulleys are biomechanically critical? A: A2 and A4.
6. Q: What is the success rate of steroid injection in non-diabetics? A: 60-90%.
7. Q: What is the success rate of steroid injection in diabetics? A: 50-60%.
8. Q: What is the success rate of open surgical release? A: > 95-100%.
9. Q: Why is percutaneous release contraindicated in the thumb? A: Radial digital nerve crosses A1 pulley obliquely.
10. Q: What is Notta's Node? A: Nodule on FPL in congenital trigger thumb (infants).
11. Q: What is the main risk of intra-tendinous steroid injection? A: Tendon necrosis and rupture.
12. Q: What happens if the A2 pulley is cut? A: Bowstringing, loss of flexion power.
13. Q: What is the Quinnell Grade 3A? A: Locked in flexion, requires passive extension.
14. Q: What is the Quinnell Grade 4? A: Fixed flexion contracture, cannot passively extend.
15. Q: Kanavel's signs indicate what? A: Septic flexor tenosynovitis (surgical emergency).

Cloze Cards (15):

1. The A1 pulley is the site of stenosis in trigger finger, located at the metacarpal head level.
2. Trigger finger prevalence in diabetics is 10-20%, compared to 2-3% in general population.
3. The A2 and A4 pulleys must be preserved to prevent bowstringing.
4. Corticosteroid injection cures trigger finger in 60-90% of non-diabetics and 50-60% of diabetics.
5. The radial digital nerve of the thumb crosses the A1 pulley, making percutaneous release contraindicated.
6. Histology of A1 pulley shows fibrocartilaginous metaplasia, collagen hypertrophy, and vascular proliferation.
7. Trigger finger is worst in the morning due to overnight tissue swelling and flexed hand posture during sleep.
8. The ring finger is most commonly affected, followed by middle, thumb, index, little.
9. Open A1 release has success rate > 95-100% with recurrence less than 1-3%.
10. Percutaneous release has success rate 80-90% with recurrence 5-10%.
11. Diabetics have multiple digit involvement more often and respond poorly to injection.
12. If high resistance during injection, you are likely intra-tendinous; action is to withdraw immediately.
13. Kanavel's four signs: fusiform swelling, flexed posture, pain on passive extension, tenderness along sheath.
14. Notta's Node is seen in congenital trigger thumb in infants, located on FPL tendon.
15. Fixed PIP contracture in Grade 4 is due to volar plate and collateral ligament shortening.

Scenario Cards (12):

1. 55F, diabetic, Grade 3 trigger ring finger. Management? A: One steroid injection trial; if fails, early surgical release (diabetics respond poorly to injection).
2. Post-injection, patient has severe pain, fusiform digit swelling, fever. Diagnosis and management? A: Septic flexor tenosynovitis; urgent surgical washout + IV antibiotics.
3. During open release, you see a white band at proximal phalanx level. Action? A: STOP. This is A2 pulley (critical); do not cut. A1 is at MCP level.
4. Patient reports clicking at PIP joint, but no tenderness there. Where do you examine? A: Palpate A1 pulley in palm at distal palmar crease (MCP level); pathology is in palm, not PIP.
5. Post-op, patient has numbness on radial side of thumb. Diagnosis? A: Radial digital nerve injury during A1 release.
6. Post A1 release, flexor tendon visibly bowstrings away from bone. Cause? A: Accidental division of A2 or A4 pulley; difficult to repair.
7. 60M, Grade 4 trigger finger, PIP fixed at 45° flexion. Will A1 release alone restore full extension? A: No; secondary PIP contracture requires prolonged therapy ± PIP capsulotomy.
8. During injection, plunger pushes back hard. What's happening and action? A: Intra-tendinous injection; withdraw needle immediately to avoid tendon rupture.
9. 8-month-old infant, thumb locked in flexion, palpable nodule at thumb MCP. Diagnosis and management? A: Congenital trigger thumb (Notta's Node); observe for spontaneous resolution; surgery if persistent > 3-4 years.
10. Patient asks why finger locks at night. Explanation? A: Hand flexed during sleep, nodule engages pulley; overnight swelling worsens stenosis.
11. Diabetic patient, HbA1c 9.5%, multiple digits triggering. Advice? A: Optimize glycemic control; consider early surgical release (poor response to injection expected).
12. Post steroid injection, patient (diabetic) has blood glucose spike to 15 mmol/L. Management? A: Reassure; transient hyperglycemia for 2-5 days post-injection is common; monitor closely.

---

(End of Enhanced Topic)